This page is provided for research and educational purposes only and does not provide medical advice, diagnosis, treatment recommendations, dosing instructions, or instructions for human use. Research findings should be interpreted within the population, model, formulation, route, outcomes, and study design reported by each cited source.
Ipamorelin (5 mg Vial)
Ipamorelin is a synthetic pentapeptide that acts as a selective growth hormone secretagogue by mimicking ghrelin at the GH secretagogue receptor[1][2]. Its key advantage is high specificity for GH release without triggering ACTH or cortisol elevation, making it one of the safer GH secretagogues with minimal off-target hormonal effects[1][3].
Quick Reference
What is Ipamorelin?
Research overview based on the cited scientific literature.
• Goal: Stimulate endogenous growth hormone release to support anabolic processes related to muscle growth, fat metabolism, and tissue repair[1][2].
• Storage: Lyophilized refrigerated or frozen; reconstituted refrigerated; use within ~4 weeks.
Storage Instructions
Proper storage preserves peptide quality.
• Lyophilized: Store at 2–8 °C (35.6–46.4 °F) for short-term or −20 °C (−4 °F) for long-term storage in dry, dark conditions[10][11].
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within ~4 weeks with bacteriostatic water[12]. For longer storage, freeze aliquots at −20 °C (−4 °F) and avoid repeated freeze–thaw cycles[11].
• Allow vials to reach room temperature before opening to reduce condensation uptake[10].
How is Ipamorelin studied?
Ipamorelin binds to the growth hormone secretagogue receptor (GHSR-1a) and stimulates the pituitary gland to release endogenous growth hormone in a pulsatile manner[1][2]. Unlike earlier growth hormone releasing peptides, ipamorelin is highly selective and does not significantly stimulate ACTH, cortisol, or prolactin release at effective doses[1][3]. After subcutaneous injection, GH levels peak within approximately 40 minutes and return to baseline by 2–3 hours[4]. This short-acting pulsatile effect makes it suitable for once-daily administration to support physiological GH patterns. Animal studies have shown that even chronic daily exposure did not significantly desensitize GH release mechanisms[5], though cycling is recommended as a precautionary measure. Ipamorelin has also demonstrated pro-motility effects in the gastrointestinal tract via GHSR-1a receptors, with preclinical and clinical studies showing it can accelerate gastric emptying[6].
What does the research report about Ipamorelin?
Observations from preclinical and clinical literature.
• Supports increases in lean body mass and improvements in recovery through GH-mediated anabolic processes[1][2].
• Enhances fat metabolism and supports favorable body composition changes over time[1].
• High selectivity for GH release with minimal impact on other hormones (ACTH, cortisol, prolactin)[1][3].
• May support improved gastric motility and digestive function[6].
• Generally well tolerated with a low incidence of side effects at typical doses[3].
• Occasional mild injection-site reactions (redness, swelling) may occur; very rare reports of water retention or increased hunger.
Research Limitations / Risk Notes
Animal studies have shown that even chronic daily exposure did not significantly desensitize GH release mechanisms[5], though cycling is recommended as a precautionary measure. Ipamorelin is generally well tolerated with a low incidence of side effects at typical doses[3]; occasional mild injection-site reactions may occur, with very rare reports of water retention or increased hunger.
Important Note
This content is provided for scientific research and educational purposes only. It does not provide medical advice, diagnosis, treatment, dosing, or administration instructions. The compounds discussed may be investigational and are not presented as approved for human use.